Membrane-type I matrix metalloproteinase (MT1-MMP) is associated with multiple forms of cancer including mammary cancer. To directly evaluate the significance of MT1-MMP expression in tumor progression and metastasis using a genetically induced cancer model, we crossed MT1-MMP-deficient mice to MMTV-polyoma virus middle T-antigen (PyMT) mice. Expression of PyMT in the MT1-MMP-deficient background consistently resulted in hyperplasia of the mammary gland as seen in wild-type PyMT littermates. Following orthotopic transplantation of PyMT þ glands into the cleared mammary fat pad of syngeneic recipient mice, MT1-MMP-deficient tumors were palpable earlier than wild-type tumors. Moreover, MT1-MMP-deficient tumors grew to the experimental end point size quicker than control tumors, but demonstrated markedly reduced ability to metastasize to the lungs of recipient mice. Accordingly, MT1-MMPdeficient mice displayed an overall reduction in metastasis count of 50%. MT1-MMP was expressed solely in the stroma of PyMT-induced tumors and those metastatic nodules that formed in the lungs were devoid of MT1-MMP expression. Stromal fibroblasts isolated from MT1-MMP-deficient tumors did not degrade type I collagen suggesting that efficient dissemination of tumor cells is dependent on stromal cell remodeling of the tumor environment. The data demonstrate directly that MT1-MMP-mediated proteolysis by stromal cells is important in the metastatic process.
Introduction
The association between tumor cell proliferation, invasive behavior and degradation of extracellular matrix is a long-standing paradigm in tumor biology (Stetler-Stevenson and Yu, 2001) . It is widely accepted that tumor cells employ proteolytic tools to degrade both basement membrane and mesenchymal matrix molecules to proliferate, expand and metastasize (Deryugina and Quigley, 2006; Gupta and Massague, 2006) . In these processes tumor cells may express either the proteolytic enzymes themselves or marshal stromal cells via paracrine signaling to elicit the proteinases that catalyse the degradation of the pericellular matrix thereby facilitating remodeling of the local matrix microenvironment (Dano et al., 1999; Pedersen et al., 2005; Kalluri and Zeisberg, 2006) .
Due to the abundance of collagen in connective tissue, the collagen-cleaving enzymes in the matrix metalloproteinase (MMP) family as well as their putative role in tumorigenesis and metastatic spread has been the subject of significant attention (Brinckerhoff and Matrisian, 2002; Egeblad and Werb, 2002; Hotary et al., 2003 Hotary et al., , 2006 Ricard-Blum and Ruggiero, 2005) . Most MMPs have been implicated, principally, in tissue remodeling during normal postnatal development, but also linked by a substantial body of circumstantial evidence to pathological processes (Egeblad and Werb, 2002; Murphy et al., 2002; Winkler and Fowlkes, 2002) . Accordingly, it has been shown that several MMPs are overexpressed in human carcinomas suggesting a role in malignant processes (Vizoso et al., 2007) .
Despite the putative connection between MMP overexpression and tumor progression the role of MMPs has turned out to be complicated. A number of studies using cancer models combined with selective ablation of the candidate gene in mice have thus proven to retard disease progression (Wilson et al., 1997; Itoh et al., 1998; Coussens et al., 2000) , while other experiments have demonstrated that MMPs have either a limited role, or in certain instances, confer a protective role in disease progression (Masson et al., 1998; Andarawewa et al., 2003; Balbin et al., 2003; McCawley et al., 2004; Pendas et al., 2004) . Collectively, these data demonstrate that the role of MMPs in disease progression is highly diverse and not solely confined to a role in tumor promotion.
Membrane-type I matrix metalloproteinase (MT1-MMP) is a potent collagenase highly expressed in human and mouse breast carcinomas, where it has been localized to both stromal and tumor epithelial cells (Okada et al., 1995; Polette et al., 1996 Polette et al., , 1997 Ueno et al., 1997; Bisson et al., 2003; Rosenthal et al., 2004; Szabova et al., 2005) . To analyse the role of MT1-MMP in an in vivo tumor model directly, we crossed mice deficient for MT1-MMP (Holmbeck et al., 1999) to a mouse strain carrying the polyoma virus middle T-antigen (PyMT) under the control of the mouse mammary tumor virus (MMTV) promoter (Guy et al., 1992) . We report here that MMTV-PyMT-induced hyperplasia of the mammary gland develops unimpeded in the absence of MT1-MMP. Moreover, orthotopic transplantation of PyMT þ /MT1-MMP-deficient mammary glands into syngeneic recipients caused development of palpable mammary tumors more rapidly than transplantation of PyMT þ /MT1-MMP-sufficient mammary glands. Remarkably, despite the more rapid growth, the number of lung metastasis from PyMT þ / MT1-MMP-deficient tumors was reduced by 50%.
Collectively, these data demonstrate that stromal cell MT1-MMP is dispensable for growth of PyMT-induced mammary carcinoma, but required for efficient metastatic spread of cells from the primary tumor to distant sites.
Results

MT1-MMP is highly expressed in experimental mammary cancer
To assess the potential role of MT1-MMP in tumor development and metastatic spread we analysed the MMTV-PyMT model of metastatic ductal mammary adenocarcinoma for expression of MT1-MMP. In situ hybridization of both normal and cancerous tissue demonstrated that MT1-MMP was expressed in the periductal stroma of normal virgin mammary gland with no expression found in the mammary epithelial cells (Figures 1a-c) . In mammary tumor tissue, this expression pattern was retained with no signal detected in epithelial cells (Figure 1e , gray arrow). In the stroma, however, the expression of MT1-MMP was robust, suggesting extensive remodeling of the stromal collagen matrix and a possible contribution of this remodeling mechanism to the progression of disease (Figure 1e , white arrows).
Tumor cells retain their proliferative capacity in an MT1-MMP-deficient environment To assay if the ability of tumor cells to proliferate and metastasize in vivo depended on MT1-MMP, we crossed an MT1-MMP-deficient mouse (Holmbeck et al., 1999) strain to MMTV-PyMT mice (Guy et al., 1992) both in congenic FVB/N background. Both MT1-MMPdeficient female mice and control littermates (N ¼ 6) carrying the PyMT transgene developed hyperplasia of the mammary gland at weaning, thus demonstrating that mammary epithelial cells retained the ability to proliferate despite the lack of MT1-MMP-mediated remodeling in the surrounding stroma. The hyperplastic tissue in the wild-type gland consisted of small discrete lesions on several of the ducts in the immature mammary epithelium (Figure 2a ). In contrast, almost the entire epithelium of the MT1-MMP-deficient gland appeared hyperplastic generating a coherent mass, which suggested that the proliferation or survival of tumor cells exceeded that of the wild type (Figure 2b ).
Tumorigenesis is accelerated in MT1-MMP-deficient mammary glands
We next asked if the prolonged growth and ensuing metastatic spread from the primary tumor would be affected by the loss of MT1-MMP.
Because MT1-MMP-deficient mice have a limited life span our ability to follow long-term tumor growth and metastasis was severely hampered. We therefore employed an orthotopic mammary gland transplantation model where upon clearing of the no. 4 fat pad in MT1-MMP in metastatic disease L Szabova et al weaning age wild-type recipients we transplanted PyMT þ mammary glands from either syngeneic wildtype or MT1-MMP-deficient neonate mice (Figure 3a) .
The recipients were subsequently monitored for growth of the transplanted tumors by regular palpation. Corroborating our initial suspicion of accelerated tumor expansion, mice with PyMT þ transplants from MT1-MMP-deficient donors developed palpable tumors significantly sooner than wild-type controls. Specifically, the tumors developing in PyMT þ /MT1-MMP-deficient glands were detected 39.8±2.2 days after transplantation, (N ¼ 29) vs 58.6±3.3 days in recipients transplanted with wild-type PyMT glands, (N ¼ 56), Po0.001 (Figure 3b ). The average time from the detection of a palpable mass until the tumor reached the 2 cm experimental end point was 139.9±4.6 days after transplantation for PyMT þ /MT1-MMP-deficient tumors while wild-type PyMT transplants reached the end point 158.2±5.9 days after transplantation (Po0.05, Figure 3c ). The average weight recorded at the end point was 1.24 ± 0.1 g (N ¼ 25) for tumors from MT1-MMP-deficient glands vs 1.36±0.07 (N ¼ 60) for wild-type mice P>0.05 (Figure 3d ). These data demonstrated that neither the initial growth, nor hyperplasia of the mammary epithelium, nor long-term tumor development was inhibited by MT1-MMP deficiency. On the contrary, tumorigenesis in this model was significantly accelerated in the absence of MT1-MMP. 
MT1-MMP in metastatic disease
L Szabova et al MT1-MMP has previously been demonstrated as an essential tool for cell proliferation in collagen matrices in vitro (Hotary et al., 2003) and MT1-MMP-deficient mice demonstrate dramatic remodeling defects in collagenrich tissues (Holmbeck et al., 1999) . Our observations of tumor growth in the MT1-MMP-deficient PyMT þ mammary glands were thus unexpected considering that remodeling of collagen might be required for tumor progression. In an effort to understand the possible reason for the more rapid growth of the tumors in the absence of MT1-MMP, we analysed nontumorigenic mammary glands from MT1-MMP-deficient mice and control littermates. MT1-MMP-deficient mammary glands, however, did not display an increase in the percentage of proliferating cells (29 ± 1.56%, n ¼ 3 vs 38 ± 2.5%, n ¼ 6), compared to wild-type glands (P ¼ 0.01). In contrast to this observation, the MT1-MMP-deficient mammary glands did contain 3615 ± 1233 cells per mm 2 compared to 2550 ± 642 cells per mm 2 in wild-type mice (Po0.001) in glands of similar size. Despite this conflict in numbers and repeated attempts to reconcile the observations, we concluded based on the total cell number that MT1-MMP-deficient mammary tissue favored cell proliferation over wild-type mammary tissue and that this advantage was reflected also in the more rapid growth of mammary tumors originating in an MT1-MMP-deficient environment.
MT1-MMP deficiency leads to reduction of metastatic spread
Because metastatic spread of cells from the primary tumor is widely perceived to depend on proteolytic Figure 2b) . Together, these data demonstrated that metastatic spread of PyMT tumor cells in the absence of MT1-MMP was significantly inhibited, effectively reducing the number of lung metastases by 50% despite the more rapid tumor progression and growth to end stage tumor size. Figure 2a) . To test the hypothesis that stromal cells isolated from the tumors could cleave collagen, we further explanted stromal fibroblasts from either PyMT/MT1-MMP-deficient mammary glands or PyMT/MT1-MMP-sufficient mammary glands for functional analysis. When plated on high-density fibrillar collagen films, mammary stromal cells from wild-type mice effectively degraded the underlying collagen matrix thus demonstrating their ability to remodel a major component of the periductal stroma (Figure 4g ). In contrast, MT1-MMP-deficient stromal cells failed to degrade the fibrillar collagen (Figure 4h ). We infer, from this observation, that stromal cell remodeling of stromal matrix components, including collagen and basement membrane components, is abrogated in MT1-MMPdeficient cells, which in turn disables efficient egress of cancer cells from the primary tumor.
Discussion
Here, we demonstrate that genetically induced mammary cancer develops in an MT1-MMP-deficient background more rapidly than in a wild-type background, however, with a significant reduction in metastatic spread. The accelerated tumorigenesis is somewhat surprising considering the substantial body of literature identifying MT1-MMP as a major factor promoting the growth of cancer cells through degradation of the ECM environment surrounding tumors (Seiki and Yana, 2003) . Both collagen and basement membrane components have been identified as substrates for MT1-MMP and proposed as barriers obstructing the proliferation and migration of tumor cells (Hotary et al., 2003 (Hotary et al., , 2006 . Conceptually, the notion that retention of cells within a restricting matrix ultimately will lead to arrest of cell proliferation and migration is attractive and supported by substantive and thorough studies dissecting the interaction of MT1-MMP expressing cells with purified matrix components or adapted tissues (Hotary et al., 2003 (Hotary et al., , 2006 . One major discrepancy between model systems and the extracellular matrix composite of the living mesenchyme, however, is the degree to which the latter may afford flexibility and permissiveness that enables protease independent movement (Wolf et al., 2003) . It is therefore not clear if stringent experimental conditions always reflect the environment encountered by tumor cells in vivo. Rather, the highest bar is raised in these experiments and demonstrates what cells may have to overcome in the process of migration beyond a barrier rich in the particular matrix component assayed-conditions differing from local proliferation in the plastic matrix of the mammary fat pad as observed in this experiment. Contrary to our assumptions, tumor cells in an MT1-MMP-depleted environment seem not only to grow as well, but they actually exceeded the growth of tumor cells in an MT1-MMP-sufficient environment. Importantly, none of the tumor cells in our model express MT1-MMP as a means of modifying the immediate surroundings while the stromal expression is very high in control animals. Our data thus argue that the expression of MT1-MMP in the periductal stroma of the mammary gland impedes proliferation of tumor cells. Despite the counterintuitive nature of this observation there is precedence for highly accelerated cell proliferation in MT1-MMPdeficient animals. For instance, tendons and ligaments display conspicuous hyperproliferation (Holmbeck et al., 1999) . We demonstrate here that similar observations can be made in the mammary gland of MT1-MMP-deficient mice without tumorigenic gland tissue, thus suggesting that the absence of MT1-MMP also here positively affects cell proliferation. The notion that MT1-MMP expression may suppress cell proliferation in certain situations or outright lead to apoptotic demise is documented previously. High levels of MT1-MMP expression are required for apoptotic demise of chondrocytes in the removal of the collagenous scaffold of certain cartilage anlagen during development, demonstrating that MT1-MMP is not exclusively associated with promitogenic activity (Holmbeck et al., 2003) . At the same time, the loss of MT1-MMP activity is associated with severely diminished cell proliferation in the collagenous environment of the epiphyseal growth plate (Holmbeck et al., 1999) . The effect of MT1-MMP on cell behavior is therefore dual, depending on localization and level of expression. We propose that MT1-MMP-dependent remodeling of the pericellular matrix in the mammary gland by stromal cells in control mice may afford diminished anchorage and in turn less favorable growth conditions for tumor cells due to partial or complete disruption of adhesion to matrix and basement membrane as compared to the conditions present when remodeling is suppressed by MT1-MMP deficiency. Furthermore, just as remodeling of extracellular matrix has been suggested to release 'matrikines' with mitogenic activity, so too may the matrix sequester or itself constitute molecules with the ability to harness cell proliferation once they are processed by proteolysis such as proposed for endostatin-like molecules (Zatterstrom et al., 2000; Tran et al., 2005) .
Unlike the retardation of tumor growth by MT1-MMP, the ability of cells to depart from the primary tumor and translocate to distant sites in this study proves to be highly dependent on MT1-MMP. The capacity of MT1-MMP to cleave substrates offering potential physical obstruction to metastatic spread is well documented and tested in several rigorous experimental settings (Hotary et al., 2003 (Hotary et al., , 2006 . Importantly, our data demonstrate how remodeling by stromal cells promotes metastatic spread of cancer cells devoid of MT1-MMP expression and suggests that paracrine stimuli of stromal cells by cancer cells induce remodeling of the matrix which is sufficient and necessary for efficient metastasis. Despite the significant reduction in the lung metastasis count in mice transplanted with MT1-MMP-deficient glands we do not observe complete abrogation of this process. We ascribe this in part to the properties of our model system in which cancer cells are retained by an MT1-MMP-deficient stroma locally, but exposed to an MT1-MMP-sufficient environment once they translocate beyond the primary tumor stroma and into the mesenchyme of the recipient. Our assay thus only measures the local egress of cells from the primary tumor rather than the global effect of MT1-MMP deficiency on later steps in the metastatic process, which potentially could serve to suppress metastasis completely. In addition, we propose that cell egress from the primary tumor could be affected by recruitment of other proteolytic enzymes. At least one molecular relative of MT1-MMP, MT3-MMP, is expressed in remodeling mammary stroma although the apparent level in metastatic disease is significantly lower that that of MT1-MMP (Szabova et al., 2005) . Moreover, we assume based on our analysis that recipient stromal cells can invade the donor stroma to some extent and provide a potential route for escape of cancer cells from the transplant (Supplementary Figure 1) . Finally, we cannot exclude the possibility that cells can migrate without an obligate requirement for degradation of the surrounding matrix as demonstrated in vitro (Wolf et al., 2003) . Taken together, these properties may very well offer a partial rescue of the defect imposed on metastatic spread by the loss of MT1-MMP and explain the lowered metastasis counts, but lack of complete abrogation.
In summary, we present here the first direct analysis of MT1-MMP function in metastatic disease using a genetically induced animal cancer model. Surprisingly, we document that primary tumor growth is accelerated by the change in proteolytic environment while the spread of cancer cells away from the primary tumor is heavily reduced.
Materials and methods
Animal husbandry
All animals utilized in this experiment were housed and handled according to animal study proposals approved by the National Institute of Dental and Craniofacial Research Animal Care and Use Committee. Mice deficient for MT1-MMP and positive for the MMTV-PyMT transgene were generated by breeding of the MT1-MMP-deficient mice (Holmbeck et al., 1999) and the MMTV-PyMT strain (Guy et al., 1992) .
Tissue processing and histology Mammary glands and tumors were harvested, fixed overnight in 4% formaldehyde in phosphate-buffered saline, embedded in paraffin and sectioned at 6 mm. Slides were processed for either H&E staining, Masson's trichrome staining, immunostaining or in situ hybridization as described in Blavier et al. (2001) .
Mammary gland transplantation
Donor mammary glands from 0-to 6-day-old female FVB/Nj mice were wild type, heterozygous or homozygous for the MT1-MMP gene and heterozygous for the MMTV-PyMT transgene. The donor glands were inserted into the cleared fat pad of 21-day-old syngeneic FVB/Nj female recipient mice (Jackson Laboratories, Bar Harbor, ME, USA) as follows: the mice were anesthetized with 2% isoflurane and the inguinal MT1-MMP in metastatic disease L Szabova et al area was swabbed thoroughly with a skin disinfectant. Gland no. 4 was accessed by a sagittal midventral incision and by a lateral incision as illustrated (Figure 3a) . The skin was detached without damage to the peritoneum and affixed to the surgical field. The blood vessels supplying the no. 4 mammary gland were cauterized and the epithelium-containing part of the mammary gland was excised leaving enough cleared fat pad behind for transplantation of the donor gland (Figure 3a) . The donor mammary gland was inserted into the recipient fat pad (Figure 3a) and the skin was subsequently closed with 7.5 Â 1.75 mm Michel wound staples (FST, Foster City, CA, USA).
Monitoring of tumor growth
Tumor growth was monitored by weekly palpation of transplanted mammary glands in a blinded study performed by the same person for the duration of the experiment. Onset of the tumor growth was defined as the time when a hard tumor mass 1 mm or bigger was palpable. Tumor size was measured through the skin by a caliper at the widest point and experimental end point was defined as 2 cm tumor size.
Enumeration of lung metastasis
Lung metastases resulting from PyMT-induced mammary gland tumors are known to express and produce calcium containing milk components (Bugge et al., 1998) detectable by alizarin red staining. Briefly, the left lobe and the inferior lobe of the lungs were fixed in 4% paraformaldehyde, post-fixed in 95% ethanol, immersed in 0.1% alizarin red solution in 95% ethanol. After 1 day, the tissue was destained in 1% KOH. This resulted in easy visualization of purple stained metastases on the semitransparent background of lung parenchyma. Metastases were counted manually.
For enumeration of metastases in sections, lungs were sectioned at 6 mm. Three sections 200 mm apart were counted.
Isolation of mammary tumor cells and stromal fibroblasts
Mammary glands from 4-to 7-week-old wild-type or MT1-MMP-deficient/PyMT þ females were finely minced and plated on tissue culture dishes in Dulbecco's modification of Eagle's medium (DMEM)/F12, 5% fetal bovine serum, glutamine, penicillin, streptomycin, gentamycin and fungizone. Following outgrowth, tumor cells were detached from the fibroblasts by brief trypsinization. This procedure was repeated several times until homogenous cell lines of tumor cells or fibroblasts were established.
Cell proliferation assay
Proliferating cells were detected using a rabbit anti-human Ki-67 antibody cross-reacting with mouse (Novocastra Laboratories, Newcastle, UK). Paraffin sections were unmasked by microwave treatment in 0.01 M citrate, treated sequentially with primary antibody diluted 1/1000, biotin-conjugated goat anti-rabbit antibody (Vector laboratories, Burlingame, CA, USA) and ABC reagent (Vector laboratories).
Cells were counted in six fields from each mouse (N ¼ 2) and given as the average number of positive cells in addition to the total number of cells per mm 2 .
Immunolocalization of GFP For GFP detection, sections were deparaffinized, gradually hydrated and subjected to heat-mediated antigen retrieval. Endogenous peroxidase activity was blocked by 3% H 2 O 2 . The sections were reacted with a rabbit polyclonal anti-GFP antibody (Abcam, Cambridge, MA, USA) and subsequently incubated with a biotinylated anti-rabbit IgG (Vector Laboratories) followed by ABC complex (Vector Laboratories). For visualization, the sections were incubated with DAB substrate and counter-stained with hematoxylin.
Phospho-p44/42 MAPK (Erk1/2) immunoblot Cells were lysed and the protein concentration determined using BCA reagent (Pierce, Rockford, IL, USA). Twenty micrograms of protein per sample was fractionated on 4-12% NuPAGE Bis-Tris gel (Invitrogen, Carlsbad, CA, USA) and transferred to nitrocellulose membranes. Following incubation with rabbit anti-phospho-p44/42MAPK antibody, protein complexes were detected with Western Breeze (Invitrogen) and chromogenic substrate according to the manufacturer's instructions.
MT1-MMP immunoblot
MT1-MMP was detected in 30 mg of protein extract as described above except membranes were incubated with a mouse anti-MT1-MMP monoclonal antibody, then reacted with a Western Breeze chemiluminescent immunodetection kit (Invitrogen).
Gelatin zymography
Conditioned medium (DMEM, Invitrogen, Gaithersburg, MD, USA) supplemented with 1.6 Â 10 À7 M 12-O-tetradecanoyl phorbol 13-acetate was collected from cell stromal cell cultures, clarified by centrifugation, fractionated on 10% gelatin gel (Invitrogen) and developed according to the manufacturer's instructions.
Statistical analysis
Data were statistically evaluated by unpaired two-tailed Student's t-test using Prism4 software.
